Data analytics startup wins LifeBridge Health, CareFirst’s innovation challenge

LifeBridge Health and CareFirst BlueCross BlueShield, both based in Baltimore, named Socially Determined, a Washington, D.C.-based data analytics startup, the winner of their inaugural pitch competition this week, according to the Baltimore Business Journal.

Advertisement

Socially Determined competed against five other finalists for the innovation challenge’s $50,000 prize, meant to aid in research and product development. The startup’s platform analyzes 130 federal and local datasets and additional community-level data to map the impact of social determinants of health across communities, and partners with health systems and insurers to identify people and groups in need of social or health interventions.

With the funding and recognition from the challenge, Socially Determined will work alongside LifeBridge, a nonprofit health system, CareFirst, the largest health insurer in Maryland, and the Baltimore City Health Department to improve the quality of care delivered to the city’s residents.

More articles about health IT:
62% of health systems are slow to scale innovation, survey finds: 5 notes
Mobile 5G service is already available in these 22 cities
Rehab clinics can now buy robotic suits for stroke treatment

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Released OR time is leaving capacity — and revenue — on the table

Wednesday, July 22
1:00 PM - 2:00 PM CDT

Presenters: Kelly Connolly, MHSA, PMPJane Yang, MHACaity Butler, MSN, RN, CNORThomas Brehmer

Advertisement

Next Up in Health IT

Advertisement

Comments are closed.